{
    "nctId": "NCT00978913",
    "briefTitle": "Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma",
    "officialTitle": "Evaluation of Dendritic Cells Transfected With Survivin, hTERT and p53 mRNA as a Treatment for Patients With Metastatic Breast Cancer or Malignant Melanoma",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Malignant Melanoma",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 31,
    "primaryOutcomeMeasure": "to evaluate the toxicity of the vaccine in combination with Cyclophosphamide",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Histological verified metastatic breast cancer or malignant melanoma, in progression\n2. \u2265 18 years\n3. the patient must be habil\n4. Performance status \u2264 1 on Zubrod-ECOG-WHO-scale\n5. Leukocytes and platelets must be \u2265normal. Hg \u2265 6.0\n6. creatinin must be normal\n7. Liverparametre \\<2.5 x normal. Bilirubin \\<30\n8. Expected survival \\> 3 months\n9. Informed consent\n\n11. At least one measurable lesion according to RECIST criteria.\n\nExclusion Criteria:\n\n1. Indication for chemotherapy\n2. Other malignancies\n3. Brain metastases\n4. severe medical condition\n5. Acute/chronic infection with ex. HIV, hepatitis, tuberculose\n6. Severe allergy\n7. Autoimmune disease\n8. Other treatment with immune suppressing agents, other anticancer agents or experimental drugs\n9. Uncontrolled hypercalcemia.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}